Global health and wellness company Herbalife Ltd. has announced plans to acquire certain assets of Bioniq, a London-based personalized supplements firm, in a move aimed at accelerating data-driven, personalized nutrition worldwide. The transaction, disclosed March 27, 2026, is expected to close in the second quarter of 2026, subject to regulatory approvals and customary conditions.
The planned acquisition underscores Herbalife’s strategy to evolve into a technology-enabled wellness platform by integrating advanced personalization tools with its global manufacturing and distribution network. The deal also reinforces the shared vision of Herbalife and its long-time global nutrition partner Cristiano Ronaldo to expand access to personalized nutrition and wellness solutions at scale.
Scaling data-driven wellness
“The future of health and wellness is becoming more personalized and informed by data,” said Stephan Gratziani, Chief Executive Officer of Herbalife. He noted that combining Bioniq’s personalization technology with Herbalife’s existing platforms will allow the company to deliver tailored nutrition to a broader global audience.
Bioniq specializes in developing personalized supplement formulas using its patented personalization engine, individual health background information, and a proprietary database of biomarkers. Its formulations are designed to serve a wide spectrum of users—from everyday consumers to elite athletes—by addressing specific nutrient deficiencies and lifestyle needs.
Building on earlier technology investments
Bioniq is set to complement Herbalife’s earlier acquisitions of Pro2col and Link BioSciences, expanding the company’s personalized nutrition portfolio across multiple delivery formats. By pairing Bioniq’s technology with Herbalife’s global manufacturing capabilities, the company aims to accelerate innovation while maintaining scale and speed.
“I founded Bioniq in 2019 with a vision to help people optimize their wellbeing through a science-driven approach to nutrition,” said Vadim Fedotov, Founder and President of Bioniq. He said joining Herbalife provides an opportunity to bring personalized nutrition to more people through a worldwide distributor network.
Cristiano Ronaldo’s role and perspective
As both a Bioniq shareholder and a long-time Herbalife nutrition partner, Ronaldo said personalized nutrition and biometrics have been central to his performance throughout his career.
“Throughout my career, biometrics and personalized nutrition have been central to helping me perform and compete at the highest level,” Ronaldo said. He added that making tailored nutrition more widely available can help people take a more informed approach to their health, wellness, and performance.
Deal structure and future opportunities
Under the agreement, Herbalife will pay a purchase price of $55 million over five years, including an initial $10 million payment at closing. The transaction also includes up to $95 million in contingent payments tied to future performance.
As part of the deal, Herbalife obtained a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides. The option gives Herbalife flexibility to assess longer-term opportunities in emerging wellness technologies in a disciplined and capital-efficient manner.
Market rollout and global reach
Bioniq’s personalized nutritional supplements are expected to be offered later this year through Herbalife’s independent distributors in select European markets and the United States, with additional countries to follow.
Founded in 1980, Herbalife operates in more than 90 markets worldwide, offering science-backed nutrition products and a direct-selling business model centered on personalized coaching and community support. Bioniq, launched in 2019, ships globally and has developed unique supplement formulas for hundreds of thousands of users based on questionnaires and blood test data.
While the company emphasized the growth potential of the transaction, Herbalife also cautioned that forward-looking statements are subject to risks and uncertainties, including global economic conditions, regulatory developments, technology adoption, and integration challenges.
Still, the planned acquisition signals a clear direction: a deeper push into personalized, data-driven nutrition—where science, technology, and global distribution converge to shape the next phase of wellness.#
